Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.56 |
| ▸ | F13A1 | P00488 | 9/20 | 0.56 |
| ▸ | TGM1 | P22735 | 6/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378926 | 1.00 | TGM2 (0.56) | TGM2F13A1TGM1PKMKMT2A | |
| SCHEMBL14490217 | 0.96 | TGM2 (0.53) | TGM2F13A1TGM1PKMKMT2A | |
| SCHEMBL2376710 | 0.87 | ABL1 (0.59) | TGM2F13A1TGM1KMT2AMEN1 | |
| SCHEMBL5436795 | 0.86 | TGM2 (0.54) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL5440864 | 0.83 | TGM2 (0.57) | TGM2F13A1TGM1PKMKMT2A | |
| SCHEMBL14490221 | 0.83 | ABL1 (0.55) | TGM2F13A1TGM1PKMKMT2A | |
| SCHEMBL18498875 | 0.83 | TGM2 (0.53) | TGM2F13A1TGM1MAPTGPR119 | |
| SCHEMBL6939462 | 0.83 | CYP3A4 (0.62) | TGM2F13A1TGM1PKMKMT2A | |
| SCHEMBL23620929 | 0.83 | TGM2 (0.62) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL30307817 | 0.83 | TGM2 (0.62) | TGM2F13A1TGM1PKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213610-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |